The stock rallied nearly 6% to Rs 572 in intra-day trade, has fallen to Rs 550 at 02:23 pm post announcements. The company informed the stock exchanges at around 02:19 pm.
In past two trading day, the stock more than 7% from Rs 525 on February 21, 2018, after falling 6% on Wednesday.
The trading volumes on the counter more than doubled with a combined 27.53 million shares changed hands on the BSE and NSE so far.
“The US FDA conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries’ Halol facility (Gujarat, India) from February 12-23, 2018. At the conclusion of the inspection, the agency issued a Form 483, with three observations,” the company said in a regulatory filing.
The company is preparing the response to the observations, which will be submitted to the US FDA within 15 business days, it added.
Sun Pharma said it is committed to addressing these observations promptly. The company remains committed to working closely with the US FDA and continues to enhance its GMP compliance on an ongoing basis.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
-
Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
-
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in